Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, currently trading at 21.36 HKD, driven by the positive results of its innovative drug, Aiduotini (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Trial Results - The key registration Phase II clinical trial (NCT05948813) for Aiduotini has been selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its importance in the medical community [1] - The trial is an open-label, multi-center, randomized controlled study focusing on NSCLC patients with EGFR mutations (L858R or 19Del) and brain metastases, comparing the efficacy and safety of Aiduotini (160mg once daily) against Osimertinib (80mg once daily) [1][2] - A total of 257 patients with EGFR mutation NSCLC and brain metastases were enrolled, with a mid-term analysis based on 224 patients showing an intracranial objective response rate (iORR) of 92.8% for the Aiduotini group compared to 76.1% for the Osimertinib group, with a statistically significant P-value of 0.0006 [2]
同源康医药-B大涨超40% 艾多替尼关键注册Ⅱ期临床成果近期荣登WCLC口头报告